# Twist Bioscience Corporation (TWST) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $124.72, market value $7.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Twist Bioscience Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 18.1×**. Each dollar of revenue is priced at 18.1×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 17.5×**. The shares trade at 17.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.2%** (5-yr avg -7.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -33.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -20.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -16.4%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -39.3%**. Return on all capital, debt included, is -39.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -21.3%**. Each dollar of assets produces -21.3% of profit.

## Growth
- **Revenue growth (1 yr): 20.3%** (3-yr 22.8%/yr, 5-yr 33.1%/yr). Revenue grew 20.3% over the last year, against 33.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 63.9%**. Earnings per share rose 63.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.5×**. It would take 1.5 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 3.64** (quick 3.64). Current assets cover the next year's liabilities 3.64 times.
- **Altman Z-score: 29.15**. A Z-score of 29.15 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Twist Bioscience Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (10 analysts). 10 analysts cover Twist Bioscience Corporation; the consensus is buy, with an average price target of $108.60 (-13% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 386.6%** (YTD 293.2%, 3-mo 80.2%). The shares are up 386.6% over twelve months including dividends.
- **From 52-week high: -19.8%** (435.3% above the low). Trading 20% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 2.69** (volatility 74%). Beta of 2.69 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TWST · Page: https://foliofundamentals.com/stocks/twst

Not investment advice.